BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/500/0.1/20.09.24 | Market Closed - Boerse Frankfurt Warrants 01:54:57 2024-05-15 pm EDT | ||
| 0.63 EUR | +34.04% |
|
| Current month | +133.33% | ||
| 1 month | +18.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
| Date | Price | Change |
|---|---|---|
| 24-05-15 | 0.63 | +34.04% |
| 24-05-14 | 0.47 | -7.84% |
| 24-05-13 | 0.51 | +24.39% |
| 24-05-10 | 0.41 | -2.38% |
| 24-05-09 | 0.42 | -19.23% |
Real-time Boerse Frankfurt Warrants
Last update May 15, 2024 at 01:54 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM8JDT |
| ISIN | DE000VM8JDT6 |
| Date issued | 2024-01-15 |
| Strike | 500 $ |
| Maturity | 2024-09-20 (128 Days) |
| Parity | 10 : 1 |
| Emission price | 1.89 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.38 € |
|---|---|
| Lowest since issue | 0.24 € |
| Spread | 0.14 € |
| Spread % | 18.67% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
437.5
USD
Average target price
462.6
USD
Spread / Average Target
+5.73%
- Stock Market
- Warrants
- Warrant